The global cerebrospinal fluid management market is estimated to grow at a CAGR of 5.3% from 2022 to 2030. Key factors driving the market growth are increasing incidences of CSF leak and growing developments for CSF management products. However, the risk associated with CSF shunts hinders the market growth.

Biosurfactants are known as surface-active compounds that can be synthesized by a selected number of natural and biobased sources. Biosurfactants are popular for their biodegradability and low eco-toxicity. Besides biodegradability, low toxicity & high production potential, biosurfactants have a high surface and interfacial activity. Biosurfactants are commercially produced from natural sources such as vegetable oil, glycerol and glucose by the addition of a non-pathogenic microorganisms.

The Global bariatric surgeries market is estimated to grow at a CAGR of 15.9% from 2022 to 2030. Key factors driving the market growth are the increasing prevalence of obesity and growing demand for minimally invasive surgeries are driving the market growth. However, the stringent regulatory policies and increase in safety concerns restrain the market growth.

The global aesthetic lasers market is estimated to grow at a CAGR of 12.3% from 2022 to 2030. Key factors driving the market growth are growing adoption of non-invasive aesthetic procedures and increasing prevalence of skin disorders along with growing awareness about beauty devices. However, risks and complications associated with procedures and stringent safety regulations hinders the market growth.

The global acute pancreatitis market is estimated to grow at a CAGR of 5.7% from 2022 to 2030. Key factors driving the market growth are rise in pancreatic cancer cases due to acute pancreatitis and rising incidences of diabetes following acute pancreatitis. However, side-effects of pancreatitis and pancreatic cancer treatments hinders the market growth.

近几年各国/地区监管机构对去中心化临床研究（DCT）都做出了不同程度的探索。人用药品技术要求国际协调理事会（ICH）发布的 E6R3 草案对远程临床试验作出了一系列原则性规定，例如允许在适当的情况下远程获取知情同意、允许远程检查和远程稽查、允许申办者在获得伦理委员会和监管机构的同意后向试验参与者直接提供试验用药品等。近年来，我国与之相关的行业政策密集出台，旨在引导新药研发创造真正的临床价值。

助消化药物从药物治疗机制角度可分为胃动力促进药物、消化酶制剂、胃酸抑制药物和消食剂 4 个种类。中国助消化药物经历了约50年的发展历史，进入20世纪前，消化不良临床治疗以胃动力促进药物为主，且药品多来源于海外品牌。2000年开始，中国用药市场开始引进促胃动力和抑酸领域的全球性新药，为患者提供更优质治疗体验。近年中国助消化药物市场已有多种原研新药上市，初步打破海外品牌垄断，本土药品优势逐渐显现。中国助消化药物市场规模在历史测算期间和未来预测期间均呈现稳步提升趋势，用药市场对助消化药物治疗机制差异化和更优疗效的追求催化竞争格局呈梯队发展。

上周（2024.03.04-2024.03.08）医药生物报收 7413.3 点，下跌 2.24%；中药Ⅱ报收 6780.04 点，下跌 0.17%；化学制药报收 9204.26 点，下跌 1.96%；生物制品报收 6980.94 点，下跌 3.59%；医药商业报收 5562.04 点，下跌 0.68%；医疗器械报收 6598.59 点，下跌 1.56%；医疗服务报收 5112.14 点，下跌 5.18%。医药板块出现回调，其中，医疗服务、生物制品跌幅较大，中药板块跌幅最小。